
PATENT



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop DD, P.O. Box 1450, Alexandria, VA, 22312-4450, on January 6, 2004.

Ginger M. Graff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/645.977

Filing Date:

August 22, 2003

Applicant(s):

Jeffrey S. Kiel, et al.

Title:

PHENYLEPHRINE TANNATE, PYRILAMINE TANNATE, AND

DEXTROMETHORPHAN TANNATE SALTS IN

PHARMACEUTICAL COMPOSITIONS

Examiner:

Unknown

Group Art Unit:

1614

Conf. No:

8380

Atty Docket No:

PEDI-16

Cincinnati, Ohio

January 6, 2004

Commissioner for Patents Mail Stop DD P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT FILED PURSUANT TO 37 CFR §§ 1.56 AND 1.97-1.98

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §\$1.97 and 1.98, the Applicants call the references listed on the attached form PTO-1449 to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. An Information Disclosure Statement with U.S.

patents is being electronically filed on even date herewith. The Applicants have enclosed a copy of all other cited references.

The Applicants respectfully believe that the cited references, either individually or in combination, do not disclose or render obvious the subject matter claimed in the present application. Nonetheless, the Applicants request that the Examiner review the references and make an independent determination of their relevance.

The Applicants do not believe that any fees are due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By:_

David E. Jefteries Reg. No. 46,800

Wood, Herron & Evans, L.L.P. 2700 Carew Tower Cincinnati, OH 45202 (513) 241-2324 (voice) (513) 421-7269 (facsimile)

SUBSTITUTE (MODIFIED)	9	U.S. DEPARTMENT OF COMMERCE										ATTY, DOCKET NO. PEDI/16				SERIAL NO. 10/645,977				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT														APPLICANT Jeffrey S. Kiel, et al.						
														H						
(Use several sheets if necessary) (37 CFR 1.98(b))													FILING DATE August 22, 2003					1614		
U.S. PATENT DOCUMENTS																				
EXAMINER		ISSUE																		FILING DATE
INITIAL	ļ	 	PA [°]	TEN	NT NUMBER				DATE			PATENTEE			CLASS		3	SUBCLASS		IF APPROPRIATE
	A.A				Ц	\sqcup										ļ	_			
	A.B	1			Ш				<u> </u>											
	A.C																			
	A.D																			
	A.E																	*		
	A.F																			
	A.G	T			П															
	A.H				\Box	ヿ														
	A.I															T				
	A.J																			
	A.K																			
					FO	REI	GN	PAT	ENTS	OR PU	BLISH	HED F	OREIGN PA	ΑTΕ	ENT A	PPLICATI	ONS	6		
					IMENT IBER				PUBLICATION DATE			COUNTRY OR PATENT OFFIC						SUBCLASS		TRANSLATION (YES/NO)
	A.L																			
-	A.M																			
	A.N																			
	A.O											i i								
	A.P																			
	A.Q																			
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)																				
	A.R	R.I Clii	R.I. Goldberg et al., <u>Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders</u> , Clinical Medicine, (Sept. 1965) 1475-1478.																	
	A.S	J.M the	1. W	eile atme	reta ento	al., <u>F</u> f alle	Ran ergi	domi c rhi	ized do nitis us	ouble-bli sing an	ind, pa acute	arallel model	groups, place, Annals of	cet Alle	oo-con ergy, \	trolled stu /ol. 64, No	dy of	f efficac (Jan. 19	y and sa 990), 63-	fety of Rynatan® in 67.
	A.T																			
EXAMINER	DATE CONSIDERED																			